Ticker Details
Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases.
IPO Date:	October 23, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.31B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.50 | 3.71%
Avg Daily Range (30 D):	$0.17 | 3.97%
Avg Daily Range (90 D):	$0.16 | 3.95%

Institutional Daily Volume
Avg Daily Volume:	3.17M
Avg Daily Volume (30 D):	14.05M
Avg Daily Volume (90 D):	13.6M

Trade Size
Avg Trade Size (Sh.):	196
Avg Trade Size (Sh.) (30 D):	348
Avg Trade Size (Sh.) (90 D):	325

Institutional Trades
Total Institutional Trades:	5,681
Avg Institutional Trade:	$2.55M
Avg Institutional Trade (30 D):	$2.99M
Avg Institutional Trade (90 D):	$2.84M
Avg Institutional Trade Volume:	.26M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.91M
Avg Closing Trade (30 D):	$5.77M
Avg Closing Trade (90 D):	$4.47M
Avg Closing Volume:	421.92K

News

Jul 17, 2026 @ 9:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Na

Jun 23, 2026 @ 11:33 PM Amgen vs. Iovance Biotherapeutics: Which Healthcar... Source: Sara Appino

Jun 19, 2026 @ 9:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Na

May 22, 2026 @ 9:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Na

May 2, 2026 @ 6:30 AM This Beaten-Down Growth Stock Could Soar 165%, Acc... Source: Prosper Junior Bakiny

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.19	$-.25	$-.33
Diluted EPS	$-.19		$-.33
Revenue	$71.43M	$67.46M	$59.95M
Gross Profit	$28.93M	$28.98M	$3.29M
Net Income / Loss	$-79.05M	$-91.25M	$-111.66M
Operating Income / Loss	$-81.04M	$-94.9M	$-113.77M
Cost of Revenue	$42.5M	$38.48M	$56.66M
Net Cash Flow	$33.44M	$25.69M	$-39.64M
PE Ratio

Splits
Sep 26, 2013	1:100
Apr 06, 2010	24:1